Ftse Mib
33.968,78
1,01%
DAX
18.175,21
1,01%
S&P 500
5.165,71
0,74%
NASDAQ
16.298,97
0,88%
Bitcoin
63.005,13
-1,56%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Europa EU Hyloris Pharmaceuticals SA (HYL) Hyloris Pharmaceuticals SA (HYL) Notizie

HYL

Hyloris Pharmaceuticals (HYL)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:HYL
DataOraFonteTitoloSimboloCompagnia
14/03/202407:00GlobeNewswire Inc.Hyloris Présente ses Résultats Annuels pour 2023 et ses PerspectivesEU:HYLHyloris Pharmaceuticals SA
14/03/202407:00GlobeNewswire Inc.Hyloris Reports Full Year Results for 2023 & Provides Business OutlookEU:HYLHyloris Pharmaceuticals SA
14/03/202406:59GlobeNewswire Inc.Communication at the request of the FSMA on the transactions with QliniqEU:HYLHyloris Pharmaceuticals SA
14/03/202406:59GlobeNewswire Inc.Communiqué à la requête de la FSMA sur les transactions avec QliniQEU:HYLHyloris Pharmaceuticals SA
08/03/202407:00GlobeNewswire Inc.Hyloris Annonce ses Résultats Financiers Annuels le 14 mars 2024EU:HYLHyloris Pharmaceuticals SA
08/03/202407:00GlobeNewswire Inc.Hyloris to Report 2023 Full-Year Results on 14 March 2024EU:HYLHyloris Pharmaceuticals SA
27/02/202418:00GlobeNewswire Inc.Hyloris Annonce le Lancement de Maxigesic® IV aux Etats-Unis ainsi que son Approbation au CanadaEU:HYLHyloris Pharmaceuticals SA
27/02/202418:00GlobeNewswire Inc.Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In CanadaEU:HYLHyloris Pharmaceuticals SA
14/02/202418:00GlobeNewswire Inc.Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental ProceduresEU:HYLHyloris Pharmaceuticals SA
14/02/202418:00GlobeNewswire Inc.Hyloris Recrute un Premier Patient dans le Cadre d'un Essai Clinique de Phase 3 portant sur son Rince-Bouche Breveté Destiné à Contrôler les Saignements lors des Interventions DentairesEU:HYLHyloris Pharmaceuticals SA
30/01/202407:00GlobeNewswire Inc.Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)EU:HYLHyloris Pharmaceuticals SA
30/01/202407:00GlobeNewswire Inc.Hyloris et Purna Female Healthcare Annoncent des Résultats Positifs de leur Essai Clinique de Phase 2 chez des Patientes atteintes de Candidose Vulvovaginale Aiguë (CVV)EU:HYLHyloris Pharmaceuticals SA
18/01/202419:00GlobeNewswire Inc.Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS)EU:HYLHyloris Pharmaceuticals SA
18/01/202419:00GlobeNewswire Inc.Hyloris Elargit son Portefeuille de Produits avec un Nouveau Produit Candidat pour le Lichen Scléreux Vulvaire (LSV)EU:HYLHyloris Pharmaceuticals SA
16/01/202419:30GlobeNewswire Inc.Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)EU:HYLHyloris Pharmaceuticals SA
16/01/202419:30GlobeNewswire Inc.La FDA Américaine Accorde la Qualification de Médicament Orphelin au PTX-252 pour le Traitement de la Leucémie Myéloïde Aiguë (LMA)EU:HYLHyloris Pharmaceuticals SA
16/01/202417:30GlobeNewswire Inc.Pleco Therapeutics receives FDA Orphan Drug DesignationEU:HYLHyloris Pharmaceuticals SA
26/12/202318:00GlobeNewswire Inc.Hyloris Annonce des Résultats Cliniques Positifs pour son Produit Valacyclovir (HY-029) en suspension oraleEU:HYLHyloris Pharmaceuticals SA
21/12/202318:30GlobeNewswire Inc.Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth SyndromeEU:HYLHyloris Pharmaceuticals SA
21/12/202318:30GlobeNewswire Inc.Hyloris élargit son Portefeuille avec un Nouveau Produit Candidat pour le Syndrome de la Bouche BrûlanteEU:HYLHyloris Pharmaceuticals SA
04/12/202307:00GlobeNewswire Inc.Hyloris announces US FDA approval for Podofilox GelEU:HYLHyloris Pharmaceuticals SA
04/12/202307:00GlobeNewswire Inc.Hyloris annonce l'approbation du Gel Podofilox par la FDA américaineEU:HYLHyloris Pharmaceuticals SA
24/10/202307:00GlobeNewswire Inc.Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in CanadaEU:HYLHyloris Pharmaceuticals SA
24/10/202307:00GlobeNewswire Inc.Hyloris annonce un accord de licence pour l'Atomoxetine Oral Liquide au CanadaEU:HYLHyloris Pharmaceuticals SA
06/09/202322:00GlobeNewswire Inc.Hyloris Pharmaceuticals Reports 2023 Half-Year Results and provides Business OutlookEU:HYLHyloris Pharmaceuticals SA
06/09/202322:00GlobeNewswire Inc.Hyloris Pharmaceuticals présente ses résultats semestriels pour 2023 et ses perspectives d'activitéEU:HYLHyloris Pharmaceuticals SA
22/06/202307:00GlobeNewswire Inc.Hyloris annonce le recrutement d’un premier patient pour son essai clinique à 4 bras concernant Alenura(TM)EU:HYLHyloris Pharmaceuticals SA
22/06/202307:00GlobeNewswire Inc.Hyloris announces enrolment of first patient in a 4-arm clinical trial of Alenura(TM)EU:HYLHyloris Pharmaceuticals SA
13/06/202317:59GlobeNewswire Inc.Hyloris shareholders approve all resolutions at the Annual General MeetingEU:HYLHyloris Pharmaceuticals SA
13/06/202317:59GlobeNewswire Inc.Les actionnaires d’Hyloris adoptent toutes les résolutions de l’Assemblée Générale AnnuelleEU:HYLHyloris Pharmaceuticals SA
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:HYL

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STLAM
Stellantis NV
BIT
RACE
Ferrari NV
BIT
AMP
Amplifon
BIT
ENI
Eni
BIT
LDO
Leonardo
BIT
STMMI
ST Microelectronics
BIT
TEN
Tenaris
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
SPM
Saipem
BIT
TIT
Telecom Italia
BIT
TRN
Terna Trasmissione Elett...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network